Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Ensysce Biosciences, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 14 | 10 | −4 |
| Shares | 184.8K | 21.3K | −163.4K (−88.5%) |
| Value | $138.2K | $103.2K | −$35.1K (−25.4%) |
New holders (4)
Institutions that held Ensysce Biosciences, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 13,433 | $65.0K | 0.01% |
| Powell Investment Advisors, LLC | 3,333 | $16.2K | 0.01% |
| Advisory Services Network, LLC | 347 | $1.69K | 0.00% |
| JPMorgan Chase & Co | 1 | $0 | 0.00% |
Sold out (8)
Institutions that held Ensysce Biosciences, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Citadel Advisors LLC | 42,277 | $31.7K |
| Two Sigma Investments, LP | 39,870 | $29.9K |
| Acadian Asset Management LLC | 26,602 | $19.0K |
| Susquehanna International Group, LLP | 17,649 | $13.2K |
| Millennium Management LLC | 14,438 | $11.0K |
| Stifel Financial Corp | 10,832 | $8.12K |
| Bank of America Corp | 6,051 | $4.54K |
| Morgan Stanley | 276 | $207 |